Cognition Therapeutics posts January 2024 investor presentation

COGNITION THERAPEUTICS INC

Presentation filed as Exhibit 99.1; covers disease-modifying medicines for neurodegenerative disorders.
No financial results, clinical data, or guidance changes included in the filing.
CEO Lisa Ricciardi signed the 8-K; presentation intended for investor discussions.

item 8.01 item 9.01

COGNITION THERAPEUTICS INC filing history →

Source: SEC EDGAR

accession 0001104659-24-001369

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.